Revenue
2020
2021
2022
2023
Immuneering Corp (IMRX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $316,952 | $2.1M | $2.3M |
| Gross profit | — | — | $0 | $158,830 | $926,888 | $1.0M |
| Research & development | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M | $15.0M |
| Operating expenses | $59.4M | $64.1M | $58.4M | $51.9M | $34.8M | $18.1M |
| Operating income | −$59.4M | −$64.1M | −$58.4M | −$51.7M | −$33.9M | −$17.1M |
| EBITDAderived | −$59.1M | −$63.7M | −$58.1M | −$51.5M | — | — |
| Net income | −$56.0M | −$61.0M | −$53.5M | −$50.5M | −$33.5M | −$17.0M |
| Basic EPSper diluted share | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 | -$3.44 |
| Diluted EPSper diluted share | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 | -$3.44 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 | Zeskind Benjamin J.PRESIDENT AND CEO | BuyClass A Common Stock | 2.4K | $4.56 | $10.9K | 2.32M |
| Jun 15, 2026Form 4 | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | BuyClass A Common Stock | 6.0K | $4.15 | $25.0K | 382.5K |
| Jan 16, 2026Form 4 | Brakewood Harold EugeneChief Business Officer | BuyClass A Common Stock | 5.3K | $4.76 | $25.0K | 11.1K |
| Jan 15, 2026Form 4 | Schall Thomas J.Director | BuyClass A Common Stock | 21.6K | $4.67 | $101.1K | 74.5K |
| Jan 15, 2026Form 4 | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | BuyClass A Common Stock | 2.3K | $4.57 | $10.5K | 376.5K |